Radiopharmaceutical company Telix Pharmaceuticals Ltd. has inked a deal worth up to AU$264 million (US$171 million) to license and develop next-generation radiopharma imaging and therapy technology targeting fibroblast activation proteins found in a wide range of cancers.
Work at Horizon Omics Biotech Ltd. has led to the identification of quinolone derivatives reported to be useful for the treatment of cancer, autoimmune diseases, viral, bacterial and fungal infections.
Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Group Co. Ltd. have patented C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.
A team from Nanjing Leads Biolabs Co. Ltd. presented the discovery and preclinical characterization of LBL-042, a novel bispecific antibody designed to simultaneously target PD-1 and LILRB1/2, with the aim of improving immune evasion of tumor microenvironment and potentially overcoming resistance to immuno-oncology therapy.
Changchun Genescience Pharmaceuticals Co. Ltd. has reported GSC-000829, a novel and selective FGFR2/FGFR3 inhibitor being developed for the potential treatment of cancer.
DAN-222 is a polymeric nanoparticle covalently conjugated with the topoisomerase I inhibitor camptothecin, which has previously demonstrated promising clinical activity in heavily pretreated patients with breast cancer (NCT05261269).
Recurrence rates and acquired treatment resistance in colorectal cancer have been linked to colorectal cancer stem cells, which are a subpopulation of slowly dividing cells within the tumor environment.
Keymed Biosciences Co. Ltd. is out-licensing global rights, excluding China, for its bispecific antibody, CM-336, to Platina Medicines Ltd. in a deal worth up to $626 million plus sales royalties.
Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms of the deal, Merck (known as MSD outside the U.S.) gains an exclusive global license to develop, manufacture and commercialize LM-299 in exchange for an up-front payment of $588 million. Shanghai-based Lanova is eligible to receive up to $2.7 billion in milestone payments associated with the technology transfer, development, regulatory approval and commercialization of LM-299 across multiple indications.
Daiichi Sankyo Co. Ltd. and Astrazeneca plc have submitted a new BLA to the U.S. FDA for accelerated approval for datopotamab deruxtecan for treating locally advanced or metastatic epidermal growth factor receptor-mutated non-small-cell lung cancer patients who have received prior systemic therapies.
RSS
